Antigen loss variants of a murine renal cell carcinoma: Implications for tumor vaccination

International Journal of Cancer

Volumn 77, Issue 1, 1998, Pages 114-122

  Kerkmann Tucek, Aida ^a   Banat, G Andŕ ^a   Cochlovius, Björn ^a   Zöller, Margot ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF KARLSRUHE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR VACCINE;

ANIMAL CELL; ARTICLE; CELL POPULATION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; KIDNEY CARCINOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; VACCINATION;

ANIMALS; ANTIGENS, CD80; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, RENAL CELL; GENE TRANSFER TECHNIQUES; HISTOCOMPATIBILITY ANTIGENS CLASS II; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; VACCINATION;

EID: 0032479138     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980703)77:1<114::AID-IJC18>3.0.CO;2-E     Document Type: Article

References (31)

1. ANGEVIN, E., KREMER, F., GAUDIN, C., HERCEND, T. and TRIEBEL, F., Analysis of T cell immune response in renal cell carcinoma: polarization to type 1-like differentiation pattern, clonal T-cell expansion and tumor-specific cytotoxicity. Int. J. Cancer, 72, 431-440 (1997).
2. ARCA, M.J., MULE, J.J. and CHANG, A.E., Genetic approaches to adoptive cellular therapy of malignancy. Semin. Oncol., 23, 108-117 (1996).
3. BAIN, C., MERROUCHE, Y., PUISIEUX, I., DUC, A., COLOMBO, M.P. and FAVROT, M., B7.1 gene transduction of human renal-cell-carcinoma cell lines restores the proliferative response and cytotoxic function of allogeneic T cells. Int. J. Cancel 67, 769-776 (1996).
4. BARKER, A.B., MARLAND, G., DE BOER, A.J., HUIJBENS, R.J., DANEN, E.H., ADEMA, G.J. and FIGDOR, C.G., Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells In vitro. Cancer Res., 55, 5330-5334 (1995).
5. BASKAR, S., Gene-modified tumour cells as cellular vaccine. Cancer Immunol. Immunother., 43, 165-173 (1996).
6. BERNHARD, H., MAEURER, M.J., JAGER, E., WÖLFEL, T., SCHNEIDER, J., KARBACH, J., SELIGER, B., HUBER, C., STORKUS, W.S., LOTZE, M.T., MEYER-ZUM-BUSCHENFELDE. K.H. and KNUTH, A., Recognition of human renal cell carcinoma and melanoma by HLA-A2-restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and up-regulated by Interferon gamma. Scand. J. Immunol., 44, 285-292 (1996).
7. BONO, A.V. and LOVIVOLO, J.A., Renal cell carcinoma - diagnosis and treatment: state of the art. Europ. Urol., 31 (Suppl. 1), 47-55 (1997).
8. BRANDLE, D., BRASSEUR, F., WEYNANTS, P., BOON, T. and VAN DEN EYNDE, B., A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J. exp. Med., 183, 2501-2508 (1996).
9. BROWNING, M., PETRONZELLI, F., BICKNELL, D., KRAUSA, P., ROWAN, A., TONKS, S., MURRAY, N., BOOMER, J. and BODMER, W., Mechanisms of loss of HLA class I expression on colorectal tumor cells. Tissue Antigens, 47, 364-371 (1996).
10. BUBENIK, J., Cytokine gene-modified vaccines in the therapy of cancer. Pharmacol. Ther., 69, 1-14 (1996).
11. CAIGNARD, A., GUILLARD, M., GAUDIN, C., ESCUDIER, B., TRIEBEL, F. and DIETRICH, P.Y., In situ demonstration of renal cell carcinoma specific T cell clones. Int. J. Cancer, 16, 564-570 (1996).
12. CELIS, E., SETTE, A. and GREY, H.M., Epitope selection and development of peptide based vaccines to treat cancer. Semin. Cancer Biol., 6, 329-336 (1995).
13. CHANG, A.E. and SHU, S., Current status of adoptive immunotherapy of cancer, Crit. Rev. Oncol Hematol., 22, 213-228 (1996).
14. FLEUREN, G.J., GORTER, A., KUPPEN, P.J., LITVINOV, S. and WAMAAR, S.O., Tumor heterogeneity and immunotherapy of cancer, Immunol. Rev., 145, 91-122 (1995).
15. GALEAE-LAURI, J., FARZANEH, F. and OAKEN, J., Novel costimulators in the immune gene therapy of cancer. Cancer Gene Ther., 3, 202-214 (1996).
16. GAUDIN, C., DIETRICH, P.Y., ROBACHE, S., GUILLARD, M., ESCUDIER, B., LACOMBE, M.J., KUMAR, A., TRIEBEL, F. and CAIGNARD, A., In vivo local expansion of clonal T cell subpopulations in renal cell carcinoma. Cancer Res., 55, 685-690 (1995).
17. MASTRANGELO, M.J., BERD, D., NATHAN, F.E. and LATTIME, B.C., Gene therapy for human cancer an essay for clinicians. Semin. Oncol., 23, 4-21 (1996).
18. MURPHY, G.P. and HRUSHESKY, W.J., A murine renal cell carcinoma. J. nat. Cancer Inst., 50, 1013-1025 (1973).
19. PARMIANI, G., ARIENTI, F., SULE-SUSO, J., MELANI, C., COLOMBO, M.P., RAMAKRSHNA, V., BELLI, F., MASCHERONI, L., RIVOLTINI, L. and CASCINELLI, N., Cytokine-based gene therapy of human tumors. An overview. Folia Biol. (Praha), 42, 305-309 (1996).
20. POST-WHITE, J., The immune system. Semin. Oncol. Nurs., 12, 89-96 (1996).
21. RESTIFO, N.P., KAWAKAMI, Y., MARINCOLA, F.M., SHAMAMIAN, P., TAG-GARSE, A., ESQUIVEL, F. and ROSENBERG, S.A., Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I. J. Immunother., 14, 182-190 (1993).
22. RESTIFO, N.P., MARINCOLA, F.M., KAWAKAMI, Y., TAUBENBERGER, J., YANNELLI, J.R. and ROSENBERG, S.A., Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. nat. Cancer Inst., 88, 100-108 (1996).
23. ROTH, J.A. and CRISTIANO, R.J., Gene therapy for cancer: what have we done and where are we going? J. nat. Cancer Inst., 89, 21-39 (1997).
24. SAITO, T., KIMURA, M., KAWASAKI, T., SATO, S. and TOMITA, Y., MHC class II antigen-associated, invariant chain on renal cell cancer may contribute to the anti-tumor immune response of the host. Cancer Lett., 115, 121-127 (1997).
25. SCHENDEL, D.J., OBEMEDER, R., FALK, C.S., JANTZER, P., KRESSENSTEIN, S., MAGET, B., HOFSTETTER, A., RIETHMULLER, G. and NOSSNER, E., Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy. J. mol. Med., 75, 400-413 (1997).
26. SIMONS, S.M., and 18 OTHERS, Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene therapy. Cancer Res., 57, 1537-1546 (1997).
27. VILE, R.G. and CHONG, H., Immunotherapy III: combinatorial molecular immunotherapy - a synthesis and suggestions. Cancer Metastasis Rev., 15, 351-364 (1996).
28. VOGELZANG, N.J., LESTINGI, T.M., SUDAKOFF, G. and KRADJIAN, S.A., Phase I study of immunotherapy of metastatic renal cell carcinoma by direct gene transfer into metastatic lesions. Hum. Gene Ther., 5, 1357-1370 (1994).
29. WALKER, PR., SAAS, P. and DIETRICH, P.Y., Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J. Immunol., 158, 4521-4524 (1997).
30. WELS, W., MORITZ, D., SCHMIDT, M., JECKE, M., HYNES, N.E. and GRONER, B., Biotechnological and gene therapeutic strategies in cancer treatment. Gene, 159, 73-80 (1995).
31. WOJTOWICZ-PRGA, S., Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J. Immunother., 20, 165-177 (1997).